Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Hughes Website

Stephen H. Hughes, Ph.D.

Selected Publications

1)  Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, Spindler J, Ferris AL, Mellors JW, Kearney MF, Coffin JM, Hughes SH.
HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells.
Science. 345: 179-83, 2014.
2)  Abram ME, Ferris AL, Das K, Quinoñes O, Shao W, Tuske S, Alvord WG, Arnold E, Hughes SH.
Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.
J. Virol. 88: 7589-7601, 2014.
Full Text Article. [Journal]
3)  Varadarajan J, McWilliams M, Hughes S.
Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations.
Proc Natl Acad Sci U S A. 110: 14747-14752, 2013.
Full Text Article. [Journal]
4)  Johnson B, Metifiot M, Ferris A, Pommier Y, Hughes S.
A homology model of HIV-1 integrase and analysis of mutations designed to test the model.
J Mol Biol. 425: 2133-2146, 2013.
Full Text Article. [Journal]
5)  Lauberth SM, Nakayama T, Wu X, Ferris AL, Tang Z, Hughes SH, Roeder RG.
H3K4me3 Interactions with TAF3 Regulate Preinitiation Complex Assembly and Selective Gene Activation.
Cell. 152: 1021-36, 2013.
6)  Zhao XZ, Smith SJ, Metifiot M, Marchand C, Boyer PL, Pommier Y, Hughes SH, Burke TR.
4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing Compounds Having High Potency Against Raltegravir-Resistant Integrase Mutants of HIV-1.
J. Med. Chem. 57: 5190-5202, 2014.
Full Text Article. [Journal]
7)  Ivetac A, Swift SE, Boyer PL, Diaz A, Naughton J, Young JA, Hughes SH, McCammon JA.
Discovery of Novel Inhibitors of HIV-1 Reverse Transcriptase Through Virtual Screening of Experimental and Theoretical Ensembles.
Chem Biol Drug Des. 83: 521-31, 2014.
8)  Zhao XZ, Smith SJ, Métifiot M, Johnson BC, Marchand C, Pommier Y, Hughes SH, Burke TR.
Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing HIV-1 Integrase Inhibitors Having High Antiviral Potency against Cells Harboring Raltegravir-Resistant Integrase Mutants.
J. Med. Chem. 57: 1573-82, 2014.
9)  De Ravin SS, Su L, Theobald N, Choi U, Macpherson JL, Poidinger M, Symonds G, Pond SM, Ferris AL, Hughes SH, Malech HL, Wu X.
Enhancers are major targets for murine leukemia virus vector integration.
J. Virol. 88: 4504-13, 2014.
10)  De Ravin SS, Gray JT, Throm RE, Spindler J, Kearney M, Wu X, Coffin JM, Hughes SH, Malderelli F, Sorrentino BP, Malech HL.
False-Positive HIV PCR Test Following Ex Vivo Lentiviral Gene Transfer Treatment of X-linked Severe Combined Immunodeficiency Vector.
Mol. Ther. 22: 244-5, 2014.
Click Here to View Expanded Bibliography.

This page was last updated on 8/13/2014.